Once-Weekly Semaglutide in Adults with Overweight or Obesity

• Published in: The New England journal of medicine Vol. 384; no. 11; pp. 989 - 1002
• Main Authors: Wilding, John P.H, Batterham, Rachel L, Calanna, Salvatore, Davies, Melanie, Van Gaal, Luc F, Lingvay, Ildiko, McGowan, Barbara M, Rosenstock, Julio, Tran, Marie T.D, Wadden, Thomas A, Wharton, Sean, Yokote, Koutaro, Zeuthen, Niels, Kushner, Robert F
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 18.03.2021
• Subjects: Adult; Adverse events; Anti-Obesity Agents - administration & dosage; Anti-Obesity Agents - adverse effects; Antidiabetics; Body composition; Body Composition - drug effects; Body Mass Index; Body weight; Body weight loss; Cardiovascular disease; Cholelithiasis - chemically induced; Clinical trials; Coronaviruses; COVID-19; Diabetes; Diabetes mellitus; Diarrhea; Diarrhea - chemically induced; Diet; Dosage; Double-Blind Method; Female; Gastrointestinal surgery; Glucagon-Like Peptide 1 - agonists; Glucagon-Like Peptides - administration & dosage; Glucagon-Like Peptides - adverse effects; Healthy Lifestyle; Humans; Hypertension; Injections, Subcutaneous; Intervention; Life Sciences; Lifestyles; Lipids - blood; Male; Middle Aged; Nausea; Nausea - chemically induced; Obesity; Obesity - complications; Obesity - drug therapy; Overweight; Pancreatitis; Placebos; Prediabetic State - complications; Public health; Risk factors; Weight control; Weight Loss - drug effects
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2032183

This double-blind study randomly assigned adults with obesity (or overweight and with one or more weight-related coexisting conditions) without diabetes to 68 weeks of once-weekly subcutaneous semaglutide (2.4 mg) or placebo, plus lifestyle intervention. Semaglutide therapy was associated with sustained, clinically relevant weight reduction.